Global Oncology Drugs Market Growth (Status and Outlook) 2024-2030

2024

Global Oncology Drugs Market Growth (Status and Outlook) 2024-2030

Name: Global Oncology Drugs Market Growth (Status and Outlook) 2024-2030
Creator: Bonafide Research
License: https://www.bonafideresearch.com/license_information

Oncology Drugs market experiences significant growth, rising from US$193.15 billion in 2023 to US$393.1 billion by 2030, with a 10.7% CAGR.

Bonafide Trust
04-01-2024
Pages : 158
Figures : 85
Tables : 163
Region : Global
Category : Lifescience
Pharmaceutical

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

Introduction

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumour. Most cancers form tumours, but not all do. Tumours may be either benign or cancerous. Benign tumours do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumours are not cancer. Malignant tumours crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumours can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumours, called secondary cancers or metastases. Malignant tumours are cancer.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

The worldwide oncology drug market is an important part of the healthcare business, offering life-saving treatments and therapies to patients suffering from various types of cancer. Oncology medications cover a wide spectrum cancer treatment, including chemotherapy, targeted therapies, immunotherapies, and hormone therapies.

Market Insights

According to Publisher’s latest study, the global Oncology Drugs market size was valued at US$ 193150 million in 2023. With growing demand in world market, the Oncology Drugs is forecast to a readjusted size of US$ 393100 million by 2030 with a CAGR of 10.7% during review period.
The industry's leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Research Consultant

Key Features:

The report on Oncology Drugs market reflects various aspects and provide valuable insights into the industry.
Market Drivers and Challenges:
Market Drivers –
Increasing Cancer Prevalence: Aging populations, lifestyle changes, and environmental factors are all contributing to an increase in the worldwide cancer burden. The rising prevalence of cancer raises the need for effective oncology medications to diagnose, treat, and manage the disease.

Developments in Precision Medicine: Precision medicine is changing cancer care by tailoring treatment to an individual's genetic and molecular profile. Oncology medications that target specific genetic abnormalities or biomarkers are becoming more common, providing better therapeutic outcomes and fewer side effects.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

Rising Investment in Research and Development: Pharmaceutical companies, research institutes, and governments are all investing heavily in cancer research and development. These investments promote innovation in drug research, clinical trials, and tailored therapy, resulting in the creation of new oncology medications.

Market Challenges –
High research Costs: The high costs of medication research, clinical trials, and regulatory compliance make it difficult for smaller pharmaceutical companies to enter the market and limit patient affordability in some locations.

Regulatory Obstacles: Stringent regulatory standards and lengthy approval processes impede market entrance for new oncology medications, reducing time-to-market and revenue creation for producers.

Drug Resistance and Safety Concerns: The formation of drug resistance mechanisms, as well as undesirable side effects, jeopardize the long-term efficacy and safety of oncology treatments, demanding ongoing monitoring and investigation.

Access Disparities: Access to oncology treatments varies by area and socioeconomic status, emphasizing the need for equitable distribution and cost policies.

Technological Developments:
Immunotherapies: Immune checkpoint inhibitors and CAR-T cell treatments are transforming cancer treatment. These medicines use the immune system to recognize and target cancer cells, resulting in long-term responses in certain forms of cancer, including melanoma, lung cancer, and hematologic malignancies.

Precision Medicine and Genomic Profiling: Advances in genomic profiling technology allow for the discovery of genetic changes and biomarkers associated with certain tumours. This information informs treatment decisions, allowing doctors to choose the most appropriate cancer medications based on an individual's tumour features.

Targeted therapies target specific molecular targets implicated in cancer growth and progression. These medications interrupt the signalling pathways that fuel tumour growth, providing more efficacy and lower toxicity than standard chemotherapy.

Recommendations and Opportunities:
Invest in R&D: Direct resources toward translational research, drug discovery, and clinical trials to accelerate the development of novel oncology medications that address unmet medical needs and developing therapeutic areas.

Collaborate Across the Ecosystem: Encourage collaborations between pharmaceutical companies, academic institutions, research organizations, and regulatory agencies to accelerate medication development, share expertise, and handle regulatory obstacles together.

Improve Access and Affordability: Use pricing methods, payment models, and patient assistance programs to increase access to cancer medications for marginalized groups while lowering financial obstacles to treatment.

Embrace Digital Health Solutions: Use digital health technologies like telemedicine, remote monitoring, and patient-centric platforms to improve patient involvement, adherence, and results across the cancer care continuum.

Market Forecasts and Future Outlook:
The global oncology pharmaceuticals market is expected to increase steadily, owing to continued innovation, an increasing cancer burden, and shifting treatment paradigms. Precision medicine, immunotherapy, and digital health advancements are projected to transform cancer care, opening up new pathways for tailored and targeted treatments. By solving issues, encouraging collaboration, and embracing innovation, stakeholders can realize the full potential of the global oncology pharmaceuticals industry, resulting in better patient outcomes and determining the future of cancer therapy.

Market Size and Growth: The research report provide an overview of the current size and growth of the Oncology Drugs market. It may include historical data, market segmentation by Type (e.g., Chemotherapy, Targeted Therapy), and regional breakdowns.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Oncology Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Oncology Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Oncology Drugs product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Oncology Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Oncology Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assesses the environmental impact and sustainability aspects of the Oncology Drugs market.

Market Segmentation:

Oncology Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Segmentation by type

Chemotherapy

Targeted Therapy

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Others

Segmentation by application

Blood Cancer

Breast Cancer

Gastrointestinal Cancer

Prostate Cancer

Respiratory or Lung Cancer

Others

Segmentation by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

Key Players

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Roche

Celgene

Novartis

Bristol-Myers Squibb

Johnson & Johnson

Merck & Co.

AstraZeneca

Pfizer

Amgen

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen

Sanofi

Bayer

Biogen Idec

Teva

Otsuka

Eisai

Merck KGaA

Gilead Sciences

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oncology Drugs Market Size 2019-2030
2.1.2 Oncology Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Oncology Drugs Segment by Type
2.2.1 Chemotherapy
2.2.2 Targeted Therapy
2.2.3 Immunotherapy (Biologic Therapy)
2.2.4 Hormonal Therapy
2.2.5 Others
2.3 Oncology Drugs Market Size by Type
2.3.1 Oncology Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Oncology Drugs Market Size Market Share by Type (2019-2024)
2.4 Oncology Drugs Segment by Application
2.4.1 Blood Cancer
2.4.2 Breast Cancer
2.4.3 Gastrointestinal Cancer
2.4.4 Prostate Cancer
2.4.5 Respiratory or Lung Cancer
2.4.6 Others
2.5 Oncology Drugs Market Size by Application
2.5.1 Oncology Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Oncology Drugs Market Size Market Share by Application (2019-2024)
3 Oncology Drugs Market Size by Player
3.1 Oncology Drugs Market Size Market Share by Players
3.1.1 Global Oncology Drugs Revenue by Players (2019-2024)
3.1.2 Global Oncology Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Oncology Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Oncology Drugs by Regions
4.1 Oncology Drugs Market Size by Regions (2019-2024)
4.2 Americas Oncology Drugs Market Size Growth (2019-2024)
4.3 APAC Oncology Drugs Market Size Growth (2019-2024)
4.4 Europe Oncology Drugs Market Size Growth (2019-2024)
4.5 Middle East & Africa Oncology Drugs Market Size Growth (2019-2024)
5 Americas
5.1 Americas Oncology Drugs Market Size by Country (2019-2024)
5.2 Americas Oncology Drugs Market Size by Type (2019-2024)
5.3 Americas Oncology Drugs Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oncology Drugs Market Size by Region (2019-2024)
6.2 APAC Oncology Drugs Market Size by Type (2019-2024)
6.3 APAC Oncology Drugs Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Oncology Drugs by Country (2019-2024)
7.2 Europe Oncology Drugs Market Size by Type (2019-2024)
7.3 Europe Oncology Drugs Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oncology Drugs by Region (2019-2024)
8.2 Middle East & Africa Oncology Drugs Market Size by Type (2019-2024)
8.3 Middle East & Africa Oncology Drugs Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Oncology Drugs Market Forecast
10.1 Global Oncology Drugs Forecast by Regions (2025-2030)
10.1.1 Global Oncology Drugs Forecast by Regions (2025-2030)
10.1.2 Americas Oncology Drugs Forecast
10.1.3 APAC Oncology Drugs Forecast
10.1.4 Europe Oncology Drugs Forecast
10.1.5 Middle East & Africa Oncology Drugs Forecast
10.2 Americas Oncology Drugs Forecast by Country (2025-2030)
10.2.1 United States Oncology Drugs Market Forecast
10.2.2 Canada Oncology Drugs Market Forecast
10.2.3 Mexico Oncology Drugs Market Forecast
10.2.4 Brazil Oncology Drugs Market Forecast
10.3 APAC Oncology Drugs Forecast by Region (2025-2030)
10.3.1 China Oncology Drugs Market Forecast
10.3.2 Japan Oncology Drugs Market Forecast
10.3.3 Korea Oncology Drugs Market Forecast
10.3.4 Southeast Asia Oncology Drugs Market Forecast
10.3.5 India Oncology Drugs Market Forecast
10.3.6 Australia Oncology Drugs Market Forecast
10.4 Europe Oncology Drugs Forecast by Country (2025-2030)
10.4.1 Germany Oncology Drugs Market Forecast
10.4.2 France Oncology Drugs Market Forecast
10.4.3 UK Oncology Drugs Market Forecast
10.4.4 Italy Oncology Drugs Market Forecast
10.4.5 Russia Oncology Drugs Market Forecast
10.5 Middle East & Africa Oncology Drugs Forecast by Region (2025-2030)
10.5.1 Egypt Oncology Drugs Market Forecast
10.5.2 South Africa Oncology Drugs Market Forecast
10.5.3 Israel Oncology Drugs Market Forecast
10.5.4 Turkey Oncology Drugs Market Forecast
10.5.5 GCC Countries Oncology Drugs Market Forecast
10.6 Global Oncology Drugs Forecast by Type (2025-2030)
10.7 Global Oncology Drugs Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Oncology Drugs Product Offered
11.1.3 Roche Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Celgene
11.2.1 Celgene Company Information
11.2.2 Celgene Oncology Drugs Product Offered
11.2.3 Celgene Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Celgene Main Business Overview
11.2.5 Celgene Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Oncology Drugs Product Offered
11.3.3 Novartis Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Information
11.4.2 Bristol-Myers Squibb Oncology Drugs Product Offered
11.4.3 Bristol-Myers Squibb Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Bristol-Myers Squibb Main Business Overview
11.4.5 Bristol-Myers Squibb Latest Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Oncology Drugs Product Offered
11.5.3 Johnson & Johnson Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Johnson & Johnson Main Business Overview
11.5.5 Johnson & Johnson Latest Developments
11.6 Merck & Co.
11.6.1 Merck & Co. Company Information
11.6.2 Merck & Co. Oncology Drugs Product Offered
11.6.3 Merck & Co. Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Merck & Co. Main Business Overview
11.6.5 Merck & Co. Latest Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Information
11.7.2 AstraZeneca Oncology Drugs Product Offered
11.7.3 AstraZeneca Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 AstraZeneca Main Business Overview
11.7.5 AstraZeneca Latest Developments
11.8 Pfizer
11.8.1 Pfizer Company Information
11.8.2 Pfizer Oncology Drugs Product Offered
11.8.3 Pfizer Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Pfizer Main Business Overview
11.8.5 Pfizer Latest Developments
11.9 Amgen
11.9.1 Amgen Company Information
11.9.2 Amgen Oncology Drugs Product Offered
11.9.3 Amgen Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Amgen Main Business Overview
11.9.5 Amgen Latest Developments
11.10 Eli Lilly
11.10.1 Eli Lilly Company Information
11.10.2 Eli Lilly Oncology Drugs Product Offered
11.10.3 Eli Lilly Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Eli Lilly Main Business Overview
11.10.5 Eli Lilly Latest Developments
11.11 AbbVie
11.11.1 AbbVie Company Information
11.11.2 AbbVie Oncology Drugs Product Offered
11.11.3 AbbVie Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 AbbVie Main Business Overview
11.11.5 AbbVie Latest Developments
11.12 Takeda
11.12.1 Takeda Company Information
11.12.2 Takeda Oncology Drugs Product Offered
11.12.3 Takeda Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Takeda Main Business Overview
11.12.5 Takeda Latest Developments
11.13 Astellas
11.13.1 Astellas Company Information
11.13.2 Astellas Oncology Drugs Product Offered
11.13.3 Astellas Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Astellas Main Business Overview
11.13.5 Astellas Latest Developments
11.14 Ipsen
11.14.1 Ipsen Company Information
11.14.2 Ipsen Oncology Drugs Product Offered
11.14.3 Ipsen Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Ipsen Main Business Overview
11.14.5 Ipsen Latest Developments
11.15 Sanofi
11.15.1 Sanofi Company Information
11.15.2 Sanofi Oncology Drugs Product Offered
11.15.3 Sanofi Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Sanofi Main Business Overview
11.15.5 Sanofi Latest Developments
11.16 Bayer
11.16.1 Bayer Company Information
11.16.2 Bayer Oncology Drugs Product Offered
11.16.3 Bayer Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Bayer Main Business Overview
11.16.5 Bayer Latest Developments
11.17 Biogen Idec
11.17.1 Biogen Idec Company Information
11.17.2 Biogen Idec Oncology Drugs Product Offered
11.17.3 Biogen Idec Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Biogen Idec Main Business Overview
11.17.5 Biogen Idec Latest Developments
11.18 Teva
11.18.1 Teva Company Information
11.18.2 Teva Oncology Drugs Product Offered
11.18.3 Teva Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Teva Main Business Overview
11.18.5 Teva Latest Developments
11.19 Otsuka
11.19.1 Otsuka Company Information
11.19.2 Otsuka Oncology Drugs Product Offered
11.19.3 Otsuka Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Otsuka Main Business Overview
11.19.5 Otsuka Latest Developments
11.20 Eisai
11.20.1 Eisai Company Information
11.20.2 Eisai Oncology Drugs Product Offered
11.20.3 Eisai Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 Eisai Main Business Overview
11.20.5 Eisai Latest Developments
11.21 Merck KGaA
11.21.1 Merck KGaA Company Information
11.21.2 Merck KGaA Oncology Drugs Product Offered
11.21.3 Merck KGaA Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.21.4 Merck KGaA Main Business Overview
11.21.5 Merck KGaA Latest Developments
11.22 Gilead Sciences
11.22.1 Gilead Sciences Company Information
11.22.2 Gilead Sciences Oncology Drugs Product Offered
11.22.3 Gilead Sciences Oncology Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.22.4 Gilead Sciences Main Business Overview
11.22.5 Gilead Sciences Latest Developments
12 Research Findings and Conclusion

List of Tables
Table 1. Oncology Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Chemotherapy
Table 3. Major Players of Targeted Therapy
Table 4. Major Players of Immunotherapy (Biologic Therapy)
Table 5. Major Players of Hormonal Therapy
Table 6. Major Players of Others
Table 7. Oncology Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Oncology Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 9. Global Oncology Drugs Market Size Market Share by Type (2019-2024)
Table 10. Oncology Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 11. Global Oncology Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 12. Global Oncology Drugs Market Size Market Share by Application (2019-2024)
Table 13. Global Oncology Drugs Revenue by Players (2019-2024) & ($ Millions)
Table 14. Global Oncology Drugs Revenue Market Share by Player (2019-2024)
Table 15. Oncology Drugs Key Players Head office and Products Offered
Table 16. Oncology Drugs Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Oncology Drugs Market Size by Regions 2019-2024 & ($ Millions)
Table 20. Global Oncology Drugs Market Size Market Share by Regions (2019-2024)
Table 21. Global Oncology Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 22. Global Oncology Drugs Revenue Market Share by Country/Region (2019-2024)
Table 23. Americas Oncology Drugs Market Size by Country (2019-2024) & ($ Millions)
Table 24. Americas Oncology Drugs Market Size Market Share by Country (2019-2024)
Table 25. Americas Oncology Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 26. Americas Oncology Drugs Market Size Market Share by Type (2019-2024)
Table 27. Americas Oncology Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 28. Americas Oncology Drugs Market Size Market Share by Application (2019-2024)
Table 29. APAC Oncology Drugs Market Size by Region (2019-2024) & ($ Millions)
Table 30. APAC Oncology Drugs Market Size Market Share by Region (2019-2024)
Table 31. APAC Oncology Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 32. APAC Oncology Drugs Market Size Market Share by Type (2019-2024)
Table 33. APAC Oncology Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 34. APAC Oncology Drugs Market Size Market Share by Application (2019-2024)
Table 35. Europe Oncology Drugs Market Size by Country (2019-2024) & ($ Millions)
Table 36. Europe Oncology Drugs Market Size Market Share by Country (2019-2024)
Table 37. Europe Oncology Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 38. Europe Oncology Drugs Market Size Market Share by Type (2019-2024)
Table 39. Europe Oncology Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 40. Europe Oncology Drugs Market Size Market Share by Application (2019-2024)
Table 41. Middle East & Africa Oncology Drugs Market Size by Region (2019-2024) & ($ Millions)
Table 42. Middle East & Africa Oncology Drugs Market Size Market Share by Region (2019-2024)
Table 43. Middle East & Africa Oncology Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 44. Middle East & Africa Oncology Drugs Market Size Market Share by Type (2019-2024)
Table 45. Middle East & Africa Oncology Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 46. Middle East & Africa Oncology Drugs Market Size Market Share by Application (2019-2024)
Table 47. Key Market Drivers & Growth Opportunities of Oncology Drugs
Table 48. Key Market Challenges & Risks of Oncology Drugs
Table 49. Key Industry Trends of Oncology Drugs
Table 50. Global Oncology Drugs Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 51. Global Oncology Drugs Market Size Market Share Forecast by Regions (2025-2030)
Table 52. Global Oncology Drugs Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 53. Global Oncology Drugs Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 54. Roche Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 55. Roche Oncology Drugs Product Offered
Table 56. Roche Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 57. Roche Main Business
Table 58. Roche Latest Developments
Table 59. Celgene Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 60. Celgene Oncology Drugs Product Offered
Table 61. Celgene Main Business
Table 62. Celgene Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 63. Celgene Latest Developments
Table 64. Novartis Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 65. Novartis Oncology Drugs Product Offered
Table 66. Novartis Main Business
Table 67. Novartis Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 68. Novartis Latest Developments
Table 69. Bristol-Myers Squibb Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 70. Bristol-Myers Squibb Oncology Drugs Product Offered
Table 71. Bristol-Myers Squibb Main Business
Table 72. Bristol-Myers Squibb Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 73. Bristol-Myers Squibb Latest Developments
Table 74. Johnson & Johnson Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 75. Johnson & Johnson Oncology Drugs Product Offered
Table 76. Johnson & Johnson Main Business
Table 77. Johnson & Johnson Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 78. Johnson & Johnson Latest Developments
Table 79. Merck & Co. Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 80. Merck & Co. Oncology Drugs Product Offered
Table 81. Merck & Co. Main Business
Table 82. Merck & Co. Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 83. Merck & Co. Latest Developments
Table 84. AstraZeneca Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 85. AstraZeneca Oncology Drugs Product Offered
Table 86. AstraZeneca Main Business
Table 87. AstraZeneca Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 88. AstraZeneca Latest Developments
Table 89. Pfizer Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 90. Pfizer Oncology Drugs Product Offered
Table 91. Pfizer Main Business
Table 92. Pfizer Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 93. Pfizer Latest Developments
Table 94. Amgen Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 95. Amgen Oncology Drugs Product Offered
Table 96. Amgen Main Business
Table 97. Amgen Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 98. Amgen Latest Developments
Table 99. Eli Lilly Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 100. Eli Lilly Oncology Drugs Product Offered
Table 101. Eli Lilly Main Business
Table 102. Eli Lilly Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 103. Eli Lilly Latest Developments
Table 104. AbbVie Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 105. AbbVie Oncology Drugs Product Offered
Table 106. AbbVie Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 107. AbbVie Main Business
Table 108. AbbVie Latest Developments
Table 109. Takeda Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 110. Takeda Oncology Drugs Product Offered
Table 111. Takeda Main Business
Table 112. Takeda Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 113. Takeda Latest Developments
Table 114. Astellas Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 115. Astellas Oncology Drugs Product Offered
Table 116. Astellas Main Business
Table 117. Astellas Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 118. Astellas Latest Developments
Table 119. Ipsen Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 120. Ipsen Oncology Drugs Product Offered
Table 121. Ipsen Main Business
Table 122. Ipsen Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 123. Ipsen Latest Developments
Table 124. Sanofi Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 125. Sanofi Oncology Drugs Product Offered
Table 126. Sanofi Main Business
Table 127. Sanofi Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 128. Sanofi Latest Developments
Table 129. Bayer Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 130. Bayer Oncology Drugs Product Offered
Table 131. Bayer Main Business
Table 132. Bayer Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 133. Bayer Latest Developments
Table 134. Biogen Idec Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 135. Biogen Idec Oncology Drugs Product Offered
Table 136. Biogen Idec Main Business
Table 137. Biogen Idec Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 138. Biogen Idec Latest Developments
Table 139. Teva Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 140. Teva Oncology Drugs Product Offered
Table 141. Teva Main Business
Table 142. Teva Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 143. Teva Latest Developments
Table 144. Otsuka Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 145. Otsuka Oncology Drugs Product Offered
Table 146. Otsuka Main Business
Table 147. Otsuka Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 148. Otsuka Latest Developments
Table 149. Eisai Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 150. Eisai Oncology Drugs Product Offered
Table 151. Eisai Main Business
Table 152. Eisai Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 153. Eisai Latest Developments
Table 154. Merck KGaA Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 155. Merck KGaA Oncology Drugs Product Offered
Table 156. Merck KGaA Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 157. Merck KGaA Main Business
Table 158. Merck KGaA Latest Developments
Table 159. Gilead Sciences Details, Company Type, Oncology Drugs Area Served and Its Competitors
Table 160. Gilead Sciences Oncology Drugs Product Offered
Table 161. Gilead Sciences Main Business
Table 162. Gilead Sciences Oncology Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 163. Gilead Sciences Latest Developments

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. Read More

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. Read More

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. Read More

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). Read More

Buy Now

Safe and Secure SSL Encrypted

Quick Contacts

Want to customize this report?

We offer 10% Free Customization at the time of purchase

Get Free Customization

I'm Available

Nikita Jabrela

Business Development Manager

Interested to schedule a FACE-TO-FACE meeting? Schedule a Call

Trusted Partners

Budget constraints? Get in touch with us for special pricing

Request Discount

Order Detail

Order Placed (21 March, 2025)
Notify To Team (21 March, 2025)
Report updation (22 March, 2025)
Report Quality Check (22 March, 2025)
Report Dispatch (23 March, 2025)

Email
Hard Copy

Research Methodology

An Adaptive Approach to Modern-day Research Needs

Get Methodology

Searching...

Global Oncology Drugs Market Growth (Status and Outlook) 2024-2030

2024